Laddar...
Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy
The phosphatidylinositol-3-kinase / Akt signaling pathway is currently one of the most exciting drug targets in oncology. However only a short time ago, the paradigm existed that drugs targeted to the four PI3K class 1 isoforms would be too toxic for use in cancer therapy due to effects on physiolog...
Sparad:
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2775557/ https://ncbi.nlm.nih.gov/pubmed/19139107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-08-0801 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|